Table 2.
Proportion of participants reporting one or more bone fractures of any type by allocation, overall and by sub-group
| Vitamin D arm (n=4176) |
Placebo arm (n=4172) |
Adjusted risk ratio (95% Cl)(1) |
P | P for interaction(2) |
||
|---|---|---|---|---|---|---|
| Overall | 268 (6.4%) | 253 (6.1%) | 1.10 (0.93 to 1.29) | 0.27 | ||
| By sex | Male | 183 (8.5%) | 164 (7.9%) | 1.11 (0.91 to 1.35) | 0.30 | 0.60 |
| Female | 85 (4.2%) | 89 (4.2%) | 0.99 (0.75 to 1.3) | 0.92 | ||
| By baseline 25(OH)D concentration(3) | <10 ng/mL | 82 (6.2%) | 73 (5.4%) | 1.13 (0.84 to 1.5) | 0.42 | 0.67 |
| ≥10 ng/mL | 186 (6.5%) | 180 (6.4%) | 1.08 (0.90 to 1.31) | 0.41 | ||
| By calcium intake | <500 mg/day | 169 (6.5%) | 162 (6.2%) | 1.11 (0.91 to 1.36) | 0.29 | 0.94 |
| ≥500 mg/day | 91 (6.2%) | 84 (5.9%) | 1.07 (0.81 to 1.41) | 0.63 |
Abbreviations: 25(OH)D3, 25-hydroxyvitamin D3. CI, confidence interval.
1,
adjusted for random effects of school and individual.
2,
P-value for treatment-by-subgroup interaction.
3,
deseasonalized values.